Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study.

Maria Antonella ZingaropoliPatrizia PasculliMarco IannettaValentina PerriMatteo TartagliaSebastiano Giuseppe CrisafulliChiara MerluzzoViola BaioneLorenzo MazzochiAmbra TagliettiFlavia PauriMarco FrontoniMarta AltieriAurelia GaetaGuido AntonelliAntonella ConteClaudio Maria MastroianniMaria Rosa Ciardi

Published in: Multiple sclerosis journal - experimental, translational and clinical (2022)

Screening of infectious diseases in DMT candidate MS patients helps to mitigate the infectious risk. During DMTs, a regular assessment of infectious risk allows to avoid discontinuing MS therapy and guarantees a higher degree of safety.

Keyphrases

multiple sclerosis
infectious diseases
mass spectrometry
end stage renal disease
newly diagnosed
ejection fraction
mesenchymal stem cells
prognostic factors
patient reported outcomes
white matter